All News

The third week in January is national Teen Cancer Awareness Week, a time to shine light on the unique medical, emotional and psychosocial needs of teens with cancer. But one organization focuses on these concerns year-round: Teen Cancer America (TCA).

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Breast cancer survivor gives ideas to cope with genetic cancer test results worry.

While the treatment of leukemia has greatly advanced since 1946, so has the organization. In the past seven decades, LRF has raised more than $75 million for its mission of conquering not only leukemia, but all blood cancers.

A major insurer takes a 20-year, first-line standard treatment off its preferred list in one market. But where will it end?

Research constantly highlights how adequate sleep impacts health outcomes. A recent meta-analysis, published in Cancer Epidemiology, Biomarkers & Prevention, delved in a bit further to see if people who stayed up all night for work had an increased chance of developing cancer.

So, wouldn't it be nice to have a quantitative way to say how deep the remission is? Historically, it’s been felt that if you just scratch the surface and get below the 5 percent blast level, you’re probably going to relapse. And if you get deeper, you might not.

Breast cancer survivor shares how she approaches her ongoing chemo brain.

Knowing that my sister gained remission gives me an immense bias, but ask the question, “Good or bad?” now and my answer may just be, “hard to tell.”

The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.

A study, conducted at Penn State College of Medicine, demonstrated that patients with melanoma who received immunotherapy while also taking a specific type of beta blocker lived longer than those who received immunotherapy alone.

Sometimes a kind gesture can mean the world to someone going through a tough time.

Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.

Some patients refer to this as their cancerversary. With two years in the rear-view mirror, I’m calling it my Everything-From-Here-On-Out-Is-Gravy Day.

The Food and Drug Administration granted a priority review to a supplemental biologics license application for Kymriah (tisagenlecleucel) to be used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma who either relapse or are not eligible for an autologous stem cell transplant.

The oldest cases of multiple myeloma and breast cancer date back to ancient Egyptian mummies.

In recent years, next-generation sequencing has allowed physicians and researchers alike to gather more genetic data for patients with gastrointestinal cancers. And while this kind of profiling continues to advance, so do treatment options for this patient population.

Many people don't realize they are putting pressure on those walking though cancer to keep a good attitude. There are days we all need to be able to acknowledge that it can be difficult.

The FDA approved a new combination for patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL).

When we are in situations in which others will see our cancer scars, do we have to explain them or worry about what someone else thinks?

Cancer isn't only a horrible disease, she's a great teacher. Here are some of the lessons she's taught me along my journey.

January is Cervical Health Awareness Month. Learn how women with cervical cancer can manage potential fertility concerns.

Breast cancer survivor tries to make rational choices based on newer genetic testing results.

A recurrence is always a possibility for any victim of cancer, but should survivors expect a recurrence? If so, how can they prepare for that possibility?

The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.

Kevin explains the delights of being both a cancer patient and an adult.

Traditionally, desmoplastic melanoma was difficult to treat because the tumor tissue is so dense. However, researchers just discovered that immunotherapy agents have potential in this space.

A male breast cancer survivor offers some alternatives to stress.